Gu Dongmin, Szallasi Arpad
Department of Pathology, Saint Barnabas Medical Center, Livingston, NJ, U.S.A.
Department of Pathology, Baptist Medical Center and Baptist - MD Anderson Cancer Center, Jacksonville, FL, U.S.A.
Anticancer Res. 2017 Sep;37(9):4717-4726. doi: 10.21873/anticanres.11878.
The current study aimed to determine the prognostic significance of thrombocytosis in patients with colorectal cancer (CRC) by a meta-analysis of the literature.
The meta-analysis followed the 2009 guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. A systematic literature review was conducted from PubMed and Web of Science for articles published up to May 15, 2015. Sixteen studies with a total of 5,619 patients met the inclusion criteria. Hazard ratios and 95% confidence intervals were retrieved from the original articles, calculated from the published Kaplan-Meier survival curves, or the corresponding authors were contacted for additional information. Heterogeneity was assessed using the I statistic and Chi-square tests. Publication bias was assessed by Begg's funnel plot, Egger's linear regression test and trim-and-fill method. Sensitivity analysis was performed to validate the reliability.
Thrombocytosis is associated with shorter overall, disease-free and cancer-specific survival. Overall survival is reduced in patients with thrombocytosis regardless of their clinical tumor stage, and ethnicity. Shortened disease-free survival is associated with elevated platelet count in the non-specific stage (I-IV), localized tumor (stage I-III), and in the Asian patient population. Thrombocytosis is further associated with reduced cancer-specific survival in the non-specific stage and in Asian patients. Finally, thrombocytosis is significantly related to female patients, colon tumor location, T3-4 stage, lymph node positivity, metastasis, undifferentiated histology and lymphatic involvement.
Thrombocytosis portends adverse prognosis in CRC, and may serve as a clinically useful marker to facilitate risk stratification and guide postoperative management.
本研究旨在通过对文献的荟萃分析来确定血小板增多症在结直肠癌(CRC)患者中的预后意义。
该荟萃分析遵循2009年系统评价和荟萃分析的首选报告项目指南。对PubMed和科学网进行了系统的文献检索,以查找截至2015年5月15日发表的文章。16项研究共纳入5619例患者,符合纳入标准。从原始文章中检索风险比和95%置信区间,根据发表的Kaplan-Meier生存曲线计算得出,或联系相应作者获取更多信息。使用I统计量和卡方检验评估异质性。通过Begg漏斗图、Egger线性回归检验和修剪填充法评估发表偏倚。进行敏感性分析以验证可靠性。
血小板增多症与总体生存期、无病生存期和癌症特异性生存期缩短相关。无论临床肿瘤分期和种族如何,血小板增多症患者的总体生存期均缩短。在非特异性分期(I-IV期)、局限性肿瘤(I-III期)以及亚洲患者群体中,无病生存期缩短与血小板计数升高有关。在非特异性分期和亚洲患者中,血小板增多症还与癌症特异性生存期缩短有关。最后,血小板增多症与女性患者、结肠肿瘤位置、T3-4期、淋巴结阳性、转移、未分化组织学和淋巴管受累显著相关。
血小板增多症预示着CRC患者预后不良,可作为临床上有助于风险分层和指导术后管理的有用标志物。